Saag M - Search Results

1

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.

Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, Stancil B, Mosteller M, Brothers C, Wannamaker P, Hughes A, Sutherland-Phillips D, Mallal S, Shaefer M; Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. Saag M, et al. Clin Infect Dis. 2008 Apr 1;46(7):1111-8. doi: 10.1086/529382. Clin Infect Dis. 2008. PMID: 18444831 Free article.

2

A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group.

Saag MS, Cloud GA, Graybill JR, Sobel JD, Tuazon CU, Johnson PC, Fessel WJ, Moskovitz BL, Wiesinger B, Cosmatos D, Riser L, Thomas C, Hafner R, Dismukes WE. Saag MS, et al. Clin Infect Dis. 1999 Feb;28(2):291-6. doi: 10.1086/515110. Clin Infect Dis. 1999. PMID: 10064246 Clinical Trial.

3

Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice.

Hoesley CJ, Saag MS, Chatham A, Kilby JM. Hoesley CJ, et al. Among authors: saag ms. Clin Infect Dis. 2000 Oct;31(4):1095-7. doi: 10.1086/318143. Clin Infect Dis. 2000. PMID: 11049795

4

Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection.

Call SA, Saag MS, Westfall AO, Raper JL, Pham SV, Tolson JM, Hellmann NS, Cloud GA, Johnson VA. Call SA, et al. Among authors: saag ms. J Infect Dis. 2001 Feb 1;183(3):401-8. doi: 10.1086/318078. Epub 2000 Dec 29. J Infect Dis. 2001. PMID: 11133371

5

Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases.

Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA. Coghlan ME, et al. Among authors: saag ms. Clin Infect Dis. 2001 Dec 1;33(11):1914-21. doi: 10.1086/323783. Epub 2001 Oct 24. Clin Infect Dis. 2001. PMID: 11692304

6

Duration of highly active antiretroviral therapy regimens.

Chen RY, Westfall AO, Mugavero MJ, Cloud GA, Raper JL, Chatham AG, Acosta EP, Taylor KH, Carter J, Saag MS. Chen RY, et al. Clin Infect Dis. 2003 Sep 1;37(5):714-22. doi: 10.1086/377271. Epub 2003 Aug 13. Clin Infect Dis. 2003. PMID: 12942406

7

Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002.

Bedimo R, Chen RY, Accortt NA, Raper JL, Linn C, Allison JJ, Dubay J, Saag MS, Hoesley CJ. Bedimo R, et al. Clin Infect Dis. 2004 Nov 1;39(9):1380-4. doi: 10.1086/424883. Epub 2004 Oct 11. Clin Infect Dis. 2004. PMID: 15494916

8

Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.

Saag MS. Saag MS. Clin Infect Dis. 2006 Jan 1;42(1):126-31. doi: 10.1086/498348. Epub 2005 Nov 23. Clin Infect Dis. 2006. PMID: 16323102 Review.

9

Distribution of health care expenditures for HIV-infected patients.

Chen RY, Accortt NA, Westfall AO, Mugavero MJ, Raper JL, Cloud GA, Stone BK, Carter J, Call S, Pisu M, Allison J, Saag MS. Chen RY, et al. Among authors: saag ms. Clin Infect Dis. 2006 Apr 1;42(7):1003-10. doi: 10.1086/500453. Epub 2006 Feb 22. Clin Infect Dis. 2006. PMID: 16511767

10

Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?

Bagchi S, Kempf MC, Westfall AO, Maherya A, Willig J, Saag MS. Bagchi S, et al. Clin Infect Dis. 2007 Jan 1;44(1):135-8. doi: 10.1086/510072. Epub 2006 Nov 28. Clin Infect Dis. 2007. PMID: 17143829

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

594 results

Search Page